Literature DB >> 12786794

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.

Britta Maecker1, Karen S Anderson, Michael S von Bergwelt-Baildon, Edie Weller, Robert H Vonderheide, Paul G Richardson, Robert L Schlossman, Isaura A Menezes, Zhinan Xia, Nikhil C Munshi, Kenneth C Anderson, Lee M Nadler, Joachim L Schultze.   

Abstract

Multiple myeloma (MM) is associated with defects of humoral and cellular immunity, however, little is known about the frequency and function of antigen-specific CD8+ T cells. Such information might be critical for the development of immunotherapy for MM patients. As a model, we assessed the frequency and proliferation of CD8+ T cells specific for HLA-A*0201-restricted immunodominant epitopes from influenza A (Inf A) and Epstein-Barr virus (EBV). Experiments in identical twins demonstrated reduced numbers of antigen-specific T cells after ex-vivo antigenic challenge in the MM twin when compared with the healthy twin. Similarly, the proliferation and frequency of EBV- and Inf A-specific T cells was also significantly reduced in a cohort of 24 previously untreated or conventionally treated MM patients when compared with 19 healthy individuals. In contrast, MM patients studied after receiving an autologous stem cell transplantation showed strikingly higher frequencies of EBV-specific T cells with potential to proliferate ex vivo, suggesting that EBV-specific T cells are readily expandable under these circumstances. These data identify an impaired response of CD8+ T cells in MM patients, which might in part explain the relatively limited success of anti-MM immunisations. Prospective studies will determine whether such immune assessment strategies may identify patients more likely to benefit from cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786794     DOI: 10.1046/j.1365-2141.2003.04375.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.

Authors:  B Maecker; M S von Bergwelt-Baildon; K S Anderson; R H Vonderheide; K C Anderson; L M Nadler; J L Schultze
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

2.  Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

Authors:  Rao H Prabhala; Dheeraj Pelluru; Mariateresa Fulciniti; Harsha K Prabhala; Puru Nanjappa; Weihua Song; Christine Pai; Samir Amin; Yu-Tzu Tai; Paul G Richardson; Irene M Ghobrial; Steven P Treon; John F Daley; Kenneth C Anderson; Jeffery L Kutok; Nikhil C Munshi
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

Review 3.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 4.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

5.  Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Authors:  Nikoletta Lendvai; Sacha Gnjatic; Erika Ritter; Michael Mangone; Wayne Austin; Karina Reyner; David Jayabalan; Ruben Niesvizky; Sundar Jagannath; Nina Bhardwaj; Selina Chen-Kiang; Lloyd J Old; Hearn Jay Cho
Journal:  Cancer Immun       Date:  2010-01-29

Review 6.  The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Authors:  Nikolaos Giannakoulas; Ioannis Ntanasis-Stathopoulos; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

7.  Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

Authors:  Adrian R Tramontana; Biju George; Aeron C Hurt; Joseph S Doyle; Katherine Langan; Alistair B Reid; Janet M Harper; Karin Thursky; Leon J Worth; Dominic E Dwyer; C Orla Morrissey; Paul D R Johnson; Kirsty L Buising; Simon James Harrison; John F Seymour; Patricia E Ferguson; Bin Wang; Justin T Denholm; Allen C Cheng; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

8.  Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Authors:  Sebastian Kobold; Tim Luetkens; Britta Marlen Bartels; Yanran Cao; York Hildebrandt; Orhan Sezer; Henrike Reinhard; Julia Templin; Katrin Bartels; Nesrine Lajmi; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic
Journal:  Clin Dev Immunol       Date:  2012-03-12

9.  Cellular immunotherapy using dendritic cells against multiple myeloma.

Authors:  Thanh-Nhan Nguyen-Pham; Youn-Kyung Lee; Hyun-Ju Lee; Mi-Hyun Kim; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Korean J Hematol       Date:  2012-03-28

10.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.